Research Report on China's Diabetes Drug Market, 2013-2017

DUBLIN, Dec. 21, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/zrrwvb/research_report) has announced the addition of the "Research Report on China's Diabetes Drug Market, 2013-2017" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Diabetes refers to a series of metabolic disorder syndrome such as sugars, proteins, fat, water and electrolyte that are triggered by islet dysfunction and insulin resistance, and the latter is caused by the actions of various pathogenic factors such as genetic factors, immune disorders, microbial infections and their toxins, free radical toxins, psychological factors on body. In recent years, with the development of China's economy and improvement in people's living standards, the incidence and morbidity rates of diabetes also present the increasing trend year by year.

In China, with the aggravation of aging degree, improvement in living standards and increase in obese groups caused by unhealthy lifestyles, the prevention and treatment of diabetes are increasingly severe. Since China carried out the first survey on diabetes epidemiology in 1980, the morbidity rate of diabetes increases from less than 1% then to about 10% currently. Following tumors and cardiovascular diseases, diabetes becomes the third-largest chronic disease severely threatening people's health. In 1994, diabetics only accounted for 2.5% of the population in China. This figure increased to 5.5% in 2002 and 9.7% in 2008.

In China, the diabetes morbidity rate of people aged above 20 has reached over 9.7%, and the morbidity rate of pre-diabetes (impaired fasting glucose and impaired glucose tolerance) has reached 15.5%. In developed regions of China, diabetics in the rural population are far less than that in the urban population. However, the morbidity rate of pre-diabetes, i.e., impaired glucose regulation, in the rural population is higher than that in the urban population, whether in developed or economically-backward areas. In economically-developed regions, the diabetes morbidity rate of the urban population is 13.6%, and that of the rural population is 16.6%. In medium-developed regions, the diabetes morbidity rate of the urban population is 15.6%, and that of the rural population is 20%. This also shows that, with the development of economy and changes in lifestyles, the rural population are potential groups who are more likely to suffer from diabetes.

Key Topics Covered:

1 Overview on Diabetes Drug Market
1.1 Analysis on Diabetes Epidemiology
1.2 Brief Introduction and Classification of Diabetes Drugs

2 Global Diabetes Drug Market
2.1 New Diabetes Drugs Approved by U.S. FDA, 2011
2.2 Overview on Global Diabetes Drug Market

3 Overall Diabetes Drug Market in China
3.1 Market Size of China's Hospital-use Diabetes Drugs
3.2 Market Shares of Major Varieties of Hospital-use Diabetes Drugs
3.3 Market Shares of Diabetes Drug Manufacturers in Hospital-use Drugs
3.4 Concentration Rate of Diabetes Drug Market
3.5 Growth Rates of Major Varieties in Hospital-use Diabetes Drug Market

4 Analysis on Major Varieties in Diabetes Drug Market
4.1 Insulin Preparations
4.2 Acarbose
4.3 Metformin
4.4 Repaglinide
4.5 Glimepiride
4.6 Rosiglitazone
4.7 Gliclazide
4.8 Gliquidone
4.9 Nateglinide
4.10 Glipizide
4.11 Others

5 Major Diabetes Drugs and Prices in China, 2012

6 Development Trends of Diabetes Drugs
6.1 Market Size Trend
6.2 Technology Trend

For more information visit http://www.researchandmarkets.com/research/zrrwvb/research_report

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net